Skip to main content
Premium Trial:

Request an Annual Quote

CytRx, Mass General Pen RNAi R&D Collaboration

NEW YORK, Oct. 9 (GenomeWeb News) - Massachusetts General Hospital and CytRx try to use RNAi technology to develop a drug to prevent and cure amyotrophic lateral sclerosis, the groups said today.
   
The agreement comes on the heels of an RNAi-based research program CytRx penned with the University of Massachusetts Medical School - from which the company recently acquired an exclusive licenses to the RNAi technology.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.